BPTH
Bio-Path Holdings, Inc.
Set alert
- YTD
- -99.50%
- 1 year
- -99.67%
- Open
- 0.0001
- Prev close
- 0.0003
- Mkt cap
- 15.09K
- Vol
- 104
- Avg vol
- 33.73K
- EPS
- -1.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0001
- Forward P/E
- -0.26
- Beta
- 0.22
- Short ratio
- 0.03
- Inst. own
- 1.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 8, 2024
- 50-d avg
- 0.8966
- 200-d avg
- 1.90
- 1y target
- 12.00
Discussion (15)
Sign in to join the discussion
On this up is the information I paid for this up 300$ a year it specifically for pharmaceutical
This is original just now the information
Don’t try to manipulate the bulls
Push it up it past phase 2 I have special app for pharmaceutical
ecent Corporate Highlights
Announced Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia. In August, Bio-Path reported positive interim data from Stage 2 of the Company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). Prexigebersen continues to be well-tolerated and has now shown compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, which exceed outcomes with combination treatment of decitabine and venetoclax.
ecent Corporate Highlights
Announced Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia. In August, Bio-Path reported positive interim data from Stage 2 of the Company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). Prexigebersen continues to be well-tolerated and has now shown compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, which exceed outcomes with combination treatment of decitabine and venetoclax.
01/08/2023 07:00AM ET
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
Buy $TYME. Hear me out. New ceo and 100m share offering. Same week they patent covid oral cure. cup and handle is being formed. Reason for red day. Past 3.18 this will blast multiples. Please do your dd and thank me later.
P.s. the new ceo of TYME is the one the ceo that sold the current cure to Pfizer. So........
Buy $TYME. Hear me out. New ceo and 100m share offering. Same week they patent covid oral cure. cup and handle is being formed. Reason for red day. Past 3.18 this will blast multiples. Please do your dad and thank me later.
P.s. the new ceo of TYME is the one the ceo that sold the current cure to Pfizer. So........